Emami (531162) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
21 Nov, 2025Executive summary
Q4 FY25 consolidated revenue grew 8% year-over-year, with core domestic business up 11% and international business rebounding 6% despite geopolitical challenges.
FY25 consolidated revenue increased 6.5% to INR 3,809 crore, with profit after tax up 11% to INR 806 crore.
Strategic focus on male grooming, D2C, healthcare, and omnichannel distribution, with new leadership and product launches to drive future growth.
Audited standalone and consolidated financial results for FY25 were approved, with auditors issuing an unmodified opinion.
Special interim dividend of 200% declared, celebrating 50 years, and major acquisition of Helios Lifestyle Limited completed.
Financial highlights
Q4 consolidated revenue was INR 963 crore (+8%), gross margin 65.9%, EBITDA INR 219 crore (+4%), PAT INR 162 crore (+9%).
FY25 consolidated revenue reached INR 3,80,919 lacs, PAT INR 80,274 lacs, EBITDA INR 1,09,322 lacs, and gross margin improved by 100 bps to 68.6%.
Dividend payout for FY25 was INR 10 per share, totaling INR 436.5 crore, representing 49–54% of PAT.
Net cash position at INR 744 crore as of March 31, 2025; cash and cash equivalents at year-end were Rs. 10,463 lacs.
Basic and diluted EPS (consolidated) for FY25 was Rs. 18.48, up from Rs. 16.55 year-over-year.
Outlook and guidance
Optimism for robust growth in FY26, supported by rising market share, household penetration, and strategic brand actions.
Focus on ramping up growth in subsidiaries, cost optimization, and omnichannel distribution.
Price growth for FY26 expected in the 2-3% range.
One manufacturing facility in Assam continues to benefit from income tax incentives until FY26.
The company expects to utilize MAT credit in future years based on projected profits.
Latest events from Emami
- Double-digit sales and profit growth, strong digital and rural segments, and interim dividend declared.531162
Q3 25/264 Feb 2026 - Flat revenue, higher margins, and strong pain management offset summer category declines.531162
Q1 25/263 Feb 2026 - Q1 FY25 delivered 10% revenue growth, margin expansion, and robust summer-led performance.531162
Q1 24/252 Feb 2026 - Q2 profit-led growth with margin expansion, new launches, and strong H2 outlook.531162
Q2 24/2515 Jan 2026 - Q3 FY25 saw 5% revenue growth, 8% PAT rise, and a total 800% interim dividend declared.531162
Q3 24/259 Jan 2026 - Q2 FY26 revenue fell 10% and profit dropped 29.7%, with a Rs. 4 interim dividend declared.531162
Q2 25/2610 Nov 2025